Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic faropenem. The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the... Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation.
- Mechanism
- Curator reviewed
Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis.
- Primary indication
- Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications.Curator reviewed
- Formula / weight
- C17H19NO8S · 397.4 g/mol (avg)
- Also known as
- Faropenem daloxate · Faropenem medoxil
- Code names
- A-0026 · BAY-56-6854 · SUN-A0026
Resolves to
JQBKWZPHJOEQAO-DVPVEWDBSA-NSMILES[H][C@]12SC(=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(=O)OCC1=C(C)OC(=O)O1)[C@@]1([H])CCCO1What you can answer from here — as of June 15, 2026
Which drugs share a target with Faropenem medoxomil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account